Exicure (XCUR) said late Thursday it received a patent in Australia covering its combination approach to cancer treatment, specifically targeting CXCR4 and GPCRx.
The patent supports the company's ongoing phase 2 clinical trial assessing the combination of GPC-100 and propranolol to treat multiple myeloma, a cancer of plasma cells.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.